Clinical trials: Breast Neoplasms, Triple-Negative
Triple Negative Breast Cancer, Breast Cancer Stage II
Implantable Microdevice for TNBC - Pilot Study
The goal of this research study is to evaluate the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of a specific drug or combination of drugs as a possible tool to evaluate the…
- Conditions
- Triple Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer
- Trial name
- NCT05774886
- Testing
- Implantable Microdevice (IMD)
- Sponsor
- Dana-Farber Cancer Institute
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer
This study evaluates what influences treatment decision-making in African American women with triple negative breast cancer. The study also aims to learn about the influence of information sources that support this…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT05071677
- Testing
- Discussion, Interview, Survey Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Triple-negative Breast Cancer
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
This is an phase II study to prelininarily evaluate the efficacy and safety of JS212 mono therapy or combination therapy in patients with recurrent or metastatic TNBC.
- Trial name
- NCT07876557
- Testing
- JS212 in combination with JS207, JS212 monotherapy, JS212 in combination with JS001
- Where
- 31 sites in China
- Volunteers
- 184 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Triple Negative Breast Cancer (TNBC)
A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
The purpose of this study is to explore the feasibility and acceptability of a nurse-led, coping, and supportive care intervention for patients with triple-negative breast cancer.
- Trial name
- RESTORE (NCT07513311)
- Testing
- RESTORE, Enhanced Usual Care
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Massachusetts General Hospital
Any Advanced Solid Tumors, Triple Negative Breast Cancer
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: Safety and tolerability of NT-I7 in combination with pembrolizumab Maximum Tolerated Dose (MTD) and/or the…
- Conditions
- Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04332653
- Testing
- NT-I7, pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 215 people
- Sponsor
- NeoImmuneTech
Triple Negative Breast Cancer
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
The primary scientific question of interest of this study is whether the combination of ociperlimab, tislelizumab and chemotherapy improves progression-free survival (PFS) compared to the combination of placebo, pembrolizumab and…
- Trial name
- AdvanTIG-211 (NCT05809895)
- Testing
- Ociperlimab, Tislelizumab, Paclitaxel
- Sponsor
- Novartis Pharmaceuticals
Estrogen Receptor Negative, HER2/Neu Negative
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
The purpose of this study is to see whether a combination of two different drugs - pembrolizumab and capecitabine - is safe, and if it might be effective in treating triple negative and hormone-refractory breast cancer.
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma
- Trial name
- NCT03044730
- Testing
- Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Triple-negative Breast Cancer
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer
- Trial name
- NCT03775928
- Testing
- Apatinib, capecitabine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Triple-negative Breast Cancer
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
Objective to evaluate the efficacy and safety of neoadjuvant therapy with Chidamide combined with chemotherapy for stage II - III triple-negative breast cancer，and to compare the efficacy and safety of chemotherapy with Chidamide…
- Trial name
- NCT04582955
- Testing
- Chidamide in combination with chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Estrogen Receptor Negative, HER2/Neu Negative
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
This phase II trial studies how well trametinib and v-akt murine thymoma viral oncogene homolog 1 (Akt) inhibitor GSK2141795 work in treating patients with triple-negative breast cancer (breast cancer cells that do not have…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT01964924
- Testing
- Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
This study assesses the performance status in stage I-III triple negative breast cancer patients who are receiving neoadjuvant chemotherapy.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04835597
- Testing
- Behavioral Assessment, Electronic Health Record Review
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Triple Negative Breast Neoplasms
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
Neoadjuvant treatment is an important part of the treatment strategy for locally advanced TNBC having established a positive and significant correlation of pathologic Complete Response (pCR) with long-term clinical benefit such…
- Trial name
- neoBREASTIM (NCT06067061)
- Testing
- Atezolizumab + RP1
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Institut Curie
Solid Tumor (Phase I), Ovarian Cancer
A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.
This study is a open-label, multicenter clinical trials. The target population is participants with locally advanced or metastatic solid tumors. A total of 204 participants are planned to be included.
- Conditions
- Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT07894874
- Testing
- YF550
- Volunteers
- 204 people
- Sponsor
- InventisBio Yiqi Beijing Limited
Triple Negative Breast Cancer, Non-small Cell Lung Cancer
A Biomarker Screening Protocol for Participants With Solid Tumors
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease…
- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
- Trial name
- START (NCT05891197)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lyell Immunopharma, Inc.
Breast Cancer Female
Personalized Vaccine for Cancer Immunotherapy
Due to their genetic instability, breast tumors that do not express receptors for Estrogens, Progestagens or amplify the Her2 / neu oncogene [called triple-negative breast cancer (TNTC)] and other tumors such as melanoma…
- Trial name
- NCT04879888
- Testing
- Peptide pulsed Dendritic cell
- Where
- Colombia
- Volunteers
- 9 people
- Sponsor
- Universidad Nacional de Colombia
Triple Negative Breast Cancer, Locally Advanced Breast Cancer
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
Patients with locally advanced unresectable or metastatic programmed cell death ligand (PD-L1) positive triple negative breast cancer (TNBC) will be treated with radiation to one-four sites of metastasis amenable to radiation…
- Conditions
- Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
- Trial name
- NCT05233696
- Testing
- Nab-paclitaxel, Paclitaxel, Radiation Therapy
- Where
- United States
- Sponsor
- University of Colorado, Denver
Triple Negative Breast Cancer, Breast Cancer
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.
- Trial name
- NeoTRACT (NCT05645380)
- Testing
- Carboplatin, Docetaxel, Doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 139 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer
A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
Study to assess the effectiveness and safety of SHR 1316, bevacizumab combined with cisplatin/carboplatin for treatment of triple-negative breast cancer brain metastases.
- Trial name
- NCT04303988
- Testing
- SHR-1316, Bevacizumab, Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fudan University
Breast Cancer
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without a immune priming with cyclophosphamide, as a…
- Trial name
- NCT02593227
- Testing
- Low dose FRα vaccine, Cyclophosphamide, High dose FRα vaccine
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Marker Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.